Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

WuXi PharmaTech Reports Excellent Q2; Raises 2013 Guidance

publication date: Aug 13, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

WuXi PharmaTech’s Q2 results showed the company is continuing its long-standing pattern of steady growth. Revenues were up 9.2% to $142 million and net income climbed 44% to $29.6 million. The company’s non-GAAP earnings were $.46 per share, which was seven cents ahead of consensus estimates. With half of 2013 now known, WuXi raised guidance for full-year 2013. More details....

Stock Symbol: (NYSE: WX)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners